Compile Data Set for Download or QSAR
maximum 50k data
Found 18 of ic50 for monomerid = 207628
TargetHistone deacetylase 3(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  700nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 3(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  700nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 3(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  700nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 3(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  740nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 1(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  2.00E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 1(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  2.00E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 1(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  2.00E+3nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 1(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  3.05E+3nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 2(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  3.73E+3nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 2(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  3.73E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 2(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  3.73E+3nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPolyamine deacetylase HDAC10(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50:  6.62E+4nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 6(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: >8.00E+4nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 5(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: >1.00E+5nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 7(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: >1.00E+5nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 4(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: >1.00E+5nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 8(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: >1.00E+5nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone deacetylase 9(Homo sapiens (Human))
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: >1.00E+5nMAssay Description:HDAC enzyme inhibition assays were performed using purified HDACs 1-10 essentially as described in Beckers et al., 2007, Int. J. Cancer., 121:1138-48...More data for this Ligand-Target Pair
In DepthDetails US Patent